Date of Publication: May 27, 2025 The newly released report titled ‘‘Liquid Biopsy Market’ offers a structured analysis of the current state and future outlook of the global market. Covering historical trends and future projections from 2025 to 2035, the study evaluates how the market size has shifted over time and what lies ahead in terms of growth and development. The report focuses on evidence-based trends, providing insights into demand shifts, market structure, and broader industry patterns.
The liquid biopsy market size is estimated to grow from USD 6.09 billion in 2024 to USD 29.8 billion by 2035, growing at a CAGR of 15.53% from 2024 to 2035.. The report assesses this growth by examining real-world data, strategic decisions made by key companies, and movement across regional markets. Rather than making speculative forecasts, it presents information in a way that supports grounded business decision-making and planning.
Source of information: - https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/279.html
The research investigates key elements influencing the market and offers a detailed breakdown of major operational categories. It explores business expansion efforts, investment themes, and product distribution strategies used across the industry. Readers are provided with a neutral overview of the ‘Liquid Biopsy Market forecast, grounded in verified insights rather than promotional narratives.
Type of Circulating Biomarker
Cell Free DNA
Cell Free RNA
Circulating Tumor DNA
Extracellular Vesicles
Other Circulating Biomarkers
Type of Sample
Blood / Plasma
Other Samples
End User
Hospitals
Research Institutes
Others
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
Key Companies Profiled
Amoy Diagnostics
ArcherDX
Biocartis
Cell Search
CellMax Life
Datar Cancer Genetics
DiaCarta, EONE-DIAGNOMICS
Exosome Diagnostics
GeneCast Biotechnology
Integrated DNA Technologies
Lucence
MDNA Life Sciences
Miltenyi Biotec
NeoGenomics
ONCODE Scientific
OncoDNA
QIAGEN
PANAGENE
Personal Genome Diagnostics
Predicin
ScreenCell
Tecan
Thermo Fisher Scientific
The report includes a dedicated analysis of major players contributing to the ‘Liquid Biopsy Market growth. Some of the top companies in ‘Liquid Biopsy include Amoy Diagnostics, ArcherDX, Biocartis, Cell Search, CellMax Life , Datar Cancer Genetics, DiaCarta, EONE-DIAGNOMICS, Exosome Diagnostics, GeneCast Biotechnology, Integrated DNA Technologies, Lucence, MDNA Life Sciences, Miltenyi Biotec, NeoGenomics , ONCODE Scientific, OncoDNA, QIAGEN, PANAGENE , Personal Genome Diagnostics, Predicin, ScreenCell , Tecan, Thermo Fisher Scientific.
These organizations have been profiled in terms of their operational scale, product offerings, and strategic initiatives. Their positions in regional and global markets are discussed with reference to product performance, market engagement, and business continuity strategies. The report highlights how these players have shaped the market over time, offering insight into their long-term direction and business focus.
The study also touches on a range of external factors such as policy changes, access to distribution networks, and market regulations. These elements play a role in shaping the trajectory of the market for ‘Liquid Biopsy and influence how companies develop and implement their strategic approaches. Regional patterns, investment outlooks, and evolving pricing structures are also evaluated to provide a well-rounded view of the ‘Liquid Biopsy industry share.
Strategic movements such as partnerships, acquisitions, and new market entries are assessed as part of the broader market landscape. The report draws attention to how businesses are responding to demand patterns, operating in changing environments, and aligning with regional policies.
Research Methodology
The report has been developed using a combination of primary and secondary research techniques. Company websites, SEC filings, investor presentations, public records, and interviews with industry participants have been utilized to build a credible and balanced dataset. These methods have ensured accurate findings and insights, enabling stakeholders to better navigate the ‘Liquid Biopsy Market and make informed decisions.
To learn more about the report or to request a customized version tailored to your business requirements, feel free to get in touch with our team. We’re here to assist with further details and support your strategic planning initiatives.
